耐多药结核患者接受贝达喹啉或德拉马尼方案的临床结局比较
该前瞻性观察研究在格鲁吉亚纳入95例耐多药结核患者,比较含贝达喹啉(n=64)或德拉马尼(n=31)方案的结局。
要点
- 贝达喹啉方案6个月痰培养转换率和良好临床结局均显著高于德拉马尼方案。
- 两组有效药物数量中位数均为4,但贝达喹啉组结局更优。
核心结论
- 在耐多药结核患者中,含贝达喹啉方案相比含德拉马尼方案与更高的痰培养转换率、更良好的临床结局及更低的获得性耐药率相关。
研究设计与样本
- 前瞻性观察性研究,在格鲁吉亚纳入100例耐多药结核患者,其中95例接受含贝达喹啉(n=64)或含德拉马尼(n=31)方案治疗。
- 每月进行痰培养、最小抑菌浓度检测和不良事件监测,采用靶向最大似然估计和超级学习法生成协变量调整后的结局比例。
主要发现
- 患者中男性占82%,中位年龄38岁,既往治疗率56%,空洞型病变率61%。
关键数值与推荐
- 贝达喹啉组有效药物数量中位数4(IQR 4-4),德拉马尼组4(IQR 3.5-5)。
- 最常见伴随药物包括利奈唑胺、氯法齐明、环丝氨酸和氟喹诺酮类。
临床怎么用
- 对于耐多药结核患者,含贝达喹啉方案可能在痰培养转换、临床结局和获得性耐药方面优于含德拉马尼方案。
- 选择方案时需综合考虑药物可及性、耐受性和耐药风险,贝达喹啉可能优先考虑。
局限性
- 观察性研究设计,样本量较小(95例),可能存在未测量混杂。
- 非随机分组,贝达喹啉组与德拉马尼组基线特征可能不完全可比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bedaquiline and delamanid are newly available drugs for treating multidrug-resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no comparison studies. METHODS: We conducted a prospective, observational study among patients with MDR-TB in Georgia who were receiving a bedaquiline- or delamanid-based treatment regimen. Monthly sputum cultures, minimal inhibitory concentration testing, and adverse event monitoring were performed. Primary outcomes were culture conversion rates and clinical outcomes. Targeted maximum likelihood estimation and super learning were utilized to produce a covariate-adjusted proportion of outcomes for each regimen. RESULTS: Among 156 patients with MDR-TB, 100 were enrolled and 95 were receiving a bedaquiline-based (n = 64) or delamanid-based (n = 31) regimen. Most were male (82%) and the median age was 38 years. Rates of previous treatment (56%) and cavitary disease (61%) were high. The most common companion drugs included linezolid, clofazimine, cycloserine, and a fluoroquinolone. The median numbers of effective drugs received among patients on bedaquiline-based (4; interquartile range [IQR], 4-4) and delamanid-based (4; IQR, 3.5-5) regimens were similar. Rates of acquired drug resistance were significantly higher among patients receiving delamanid versus bedaquiline (36% vs 10%, respectively; P < .01). Adjusted rates of sputum culture conversion at 2 months (67% vs 47%, respectively; P = .10) and 6 months (95% vs 74%, respectively; P < .01), as well as more favorable clinical outcomes (96% vs 72%, respectively; P < .01), were higher among patients receiving bedaquiline versus delamanid. CONCLUSIONS: Among patients with MDR-TB, bedaquiline-based regimens were associated with higher rates of sputum culture conversion, more favorable outcomes, and a lower rate of acquired drug resistance versus delamanid-based regimens.
引用
- Kempker RR, Mikiashvili L, Zhao Y, et al. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens. Clin Infect Dis. 2020. PMID: 31712809. doi:10.1093/cid/ciz1107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。